Testing the virus therapy THEO-260 for ovarian cancer
Part of Cancer, Hormones & metabolism, Women’s health & pregnancy clinical trials.
This trial tests a new virus-based medicine called THEO-260 for people with a certain type of ovarian cancer that no longer responds to standard platinum chemo. The goal is to see if this treatment can shrink tumors or slow the cancer down.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a type of ovarian, fallopian tube, or primary peritoneal cancer called high-grade serous or endometrioid.
- Your cancer did not respond well to platinum chemo, or it came back within 6 months of finishing it.
- You are generally able to take care of yourself (ECOG score 0 or 1) and expected to live more than 3 months.
- You have not had cancer treatment (chemo, radiation, or another experimental drug) in the last month.
- You do not have serious infections, autoimmune disease, major heart or lung problems, or other conditions that would make this treatment unsafe.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests an investigational drug called THEO-260, given directly into the belly (intraperitoneal), for people with advanced ovarian, fallopian tube, or primary peritoneal cancer that has stopped responding to platinum chemotherapy. The goal is to see if it is safe and effective.
This study tests a new medicine called TUB-040, given together with standard ovarian cancer drugs like carboplatin and bevacizumab. It is for women with ovarian cancer that has returned after responding to platinum-based chemotherapy and is growing again. The goal is to see if this combination can help control the cancer.
This study tests a new drug (INCB123667) given as a pill, compared to standard chemotherapy, for people whose ovarian cancer has stopped responding to platinum-based treatments and whose tumor has high levels of a protein called Cyclin E1. The goal is to see if the new drug works better than standard chemo for this specific type of cancer.
This trial tests a new targeted drug, SHR-A1811, combined with chemotherapy for women whose ovarian cancer has returned but still responds to platinum-based drugs. The goal is to see if the combination works better than chemotherapy alone.
This trial tests a new combination of treatments for advanced ovarian, fallopian tube, or peritoneal cancer. It combines chemotherapy and immunotherapy (drugs that help your immune system fight cancer) with a special vaccine made from your own tumor. The goal is to see if this approach is more effective than standard treatment.
This study tests a new drug called TUB-040 for people with ovarian cancer that has stopped responding to platinum chemotherapy, or with a type of lung cancer that has returned or spread. The drug is designed to target cancer cells and deliver a powerful anti-cancer agent directly to them, potentially slowing the disease.
Hear when a new Ovarian cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.